Compound for treating cystic fibrosis
Provided herein is a compound represented by Formula I: or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. Also provided are pharmaceutical compositions comprising the compound noted above, in combination with a pharmaceutically acceptable excipient.
1. A compound having the formula:
or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof.
2. The compound of claim 1 , having the formula:
3. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.
4. The pharmaceutical composition of claim 3 , wherein said composition is formulated for oral delivery.
5. The pharmaceutical composition of claim 3 , in a tablet, lozenge or capsule form.
6. The pharmaceutical composition of claim 3 , in a tablet form.
7. A method of treating cystic fibrosis in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of claim 1 .
8. A method in accordance with claim 7 , wherein said compound is administered orally.
9. A method in accordance with claim 7 , wherein said compound is administered in the form of a tablet, capsule or lozenge.
10. A method of treating cystic fibrosis in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition according to claim 3 .
11. A method in accordance with claim 10 , wherein said subject is a human having a mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) protein selected from the group consisting of E56K, G178R, S549R, K1060T, G1244E, P67L, E193K, G551D, A1067T, S1251N, R74W, L206W, G551S, G1069R, S1255P, D110E, R347H, D579G, R1070Q, D1270N, D110H, R352Q, S945L, R1070W, G1349D, R117C, A455E, S977F, F1074L, R117H, S549N, F1052V, and D1152H.
12. A method of treating cystic fibrosis in a subject in need thereof, said method comprising administering to said subject an amount of a compound of claim 1 , and a second therapeutic agent.
13. A method in accordance with claim 12 , wherein said second therapeutic agent is selected from the group consisting of lung surfactants, respiratory stimulants, 5-HT4 receptor agonists and agents for treating respiratory depression.
14. A method in accordance with claim 13 , wherein said second therapeutic agent is lumacaftor.